YH-001 is under clinical development by Eucure (Beijing) Biopharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YH-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YH-001 is under development for the treatment of advanced solid tumors, melanoma, gastroesophageal (GE) junction carcinomas, advanced non-small cell lung cancer (NSCLC), soft tissue sarcoma, chondrosarcoma, leiomyosarcoma, dedifferentiated liposarcoma and hepatocellular carcinoma (HCC). The drug candidate is a tumor immune checkpoint antibody. It acts by targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). It is developed based on hybridoma technology. It is administered through intravenous route.
Eucure (Beijing) Biopharma overview
Eucure (Beijing) Biopharma is a biotechnology company that discovery and development of innovative immuno-oncology targeted antibodies. The company is headquartered China.
For a complete picture of YH-001’s drug-specific PTSR and LoA scores, buy the report here.